SG10201600950TA - Recombinant monovalent antibodies and methods for production thereof - Google Patents

Recombinant monovalent antibodies and methods for production thereof

Info

Publication number
SG10201600950TA
SG10201600950TA SG10201600950TA SG10201600950TA SG10201600950TA SG 10201600950T A SG10201600950T A SG 10201600950TA SG 10201600950T A SG10201600950T A SG 10201600950TA SG 10201600950T A SG10201600950T A SG 10201600950TA SG 10201600950T A SG10201600950T A SG 10201600950TA
Authority
SG
Singapore
Prior art keywords
production
methods
monovalent antibodies
recombinant monovalent
recombinant
Prior art date
Application number
SG10201600950TA
Other languages
English (en)
Inventor
Paul Parren
Janine Schuurman
Tom Vink
Willem Karel Bleeker
De Winkel Jan G J Van
Berkel Patrick Van
Frank Beurskens
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Publication of SG10201600950TA publication Critical patent/SG10201600950TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
SG10201600950TA 2005-11-28 2006-11-28 Recombinant monovalent antibodies and methods for production thereof SG10201600950TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74040305P 2005-11-28 2005-11-28
US85247906P 2006-10-17 2006-10-17
US85261106P 2006-10-18 2006-10-18

Publications (1)

Publication Number Publication Date
SG10201600950TA true SG10201600950TA (en) 2016-03-30

Family

ID=37781799

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201600950TA SG10201600950TA (en) 2005-11-28 2006-11-28 Recombinant monovalent antibodies and methods for production thereof

Country Status (10)

Country Link
US (3) US10155816B2 (fr)
EP (1) EP1973576B1 (fr)
JP (3) JP5525729B2 (fr)
KR (2) KR20080090406A (fr)
AU (1) AU2006317242A1 (fr)
BR (1) BRPI0619056A2 (fr)
CA (1) CA2631184A1 (fr)
EA (1) EA016609B1 (fr)
SG (1) SG10201600950TA (fr)
WO (1) WO2007059782A1 (fr)

Families Citing this family (387)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057179A2 (fr) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Utilisation de p97 en tant que systeme d'administration d'enzymes en vue d'administrer des enzymes lysosomales therapeutiques
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
CA2631184A1 (fr) 2005-11-28 2007-05-31 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
US9181344B2 (en) 2005-12-15 2015-11-10 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
CA2656620C (fr) 2006-07-04 2018-03-13 Genmab A/S Molecules de liaison a cd20 pour le traitement de copd
CA2662350A1 (fr) 2006-09-05 2008-03-13 Medarex, Inc. Anticorps contre les proteines morphogeniques osseuses et les recepteurs de celles-ci et procedes d'utilisation de ceux-ci
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
US8481683B2 (en) 2006-12-01 2013-07-09 Medarex, Inc. Human antibodies that bind CD22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
MX2009006277A (es) 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
AU2013202392B2 (en) * 2006-12-20 2016-02-25 Mmrglobal, Inc. Antibodies and methods for making and using them
EP2121756A4 (fr) * 2006-12-20 2011-08-31 Mmrglobal Inc Anticorps et procedes de fabrication et d'utilisation de ceux-ci
EP3118221B1 (fr) 2007-02-26 2019-08-21 Oxford BioTherapeutics Ltd Proteines
WO2008104803A2 (fr) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Protéines
ES2593484T3 (es) * 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
EP2599791A1 (fr) * 2007-04-27 2013-06-05 Genentech, Inc. Anticorps anti-CD4 puissants, stables et non immunosuppresseurs
WO2008145140A2 (fr) * 2007-05-31 2008-12-04 Genmab A/S Animaux transgéniques produisant des anticorps humains monovalents et anticorps pouvant s'obtenir à partir de ces animaux
EP2152751A1 (fr) * 2007-05-31 2010-02-17 Genmab A/S Protéines de fusion ou liéee à demi-vie étendue
JP5511654B2 (ja) * 2007-05-31 2014-06-04 ゲンマブ エー／エス 分子操作により得られた組換え非グリコシル化一価半抗体
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US20100255012A1 (en) * 2007-05-31 2010-10-07 Genmab A/S Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering
CA2687896A1 (fr) 2007-06-05 2008-12-18 Yale University Anticorps dirige contre le domaine de type ig d4 du recepteur kit
JP5588866B2 (ja) 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
US9062097B2 (en) * 2007-08-21 2015-06-23 Morpho Sys AG Methods for the formation of disulphide bonds
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
CA2699394C (fr) 2007-09-17 2020-03-24 The Regents Of The University Of California Anticorps monoclonaux humains internalisants ciblant des cellules du cancer de la prostate in situ
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
MX2010003329A (es) 2007-09-26 2010-04-27 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6.
US8497355B2 (en) * 2007-09-28 2013-07-30 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
WO2009054001A1 (fr) * 2007-10-22 2009-04-30 Biocon Limited Composition pharmaceutique et procédé correspondant
US20090148905A1 (en) 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
PT2594590E (pt) 2007-12-14 2015-01-14 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
EP2080770A1 (fr) * 2008-01-21 2009-07-22 MorphoSys AG Molécules à liaison protéique comprenant des étiquettes de purification
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2316030B1 (fr) 2008-07-25 2019-08-21 Wagner, Richard W. Procédés de criblage de protéines
AU2009324092A1 (en) * 2008-12-03 2011-06-23 Genmab A/S Antibody variants having modifications in the constant region
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
AU2010207552A1 (en) 2009-01-21 2011-09-01 Oxford Biotherapeutics Ltd. PTA089 protein
WO2010085590A1 (fr) 2009-01-23 2010-07-29 Biosynexus Incorporated Anticorps opsoniques et protecteurs spécifiques de bactéries à gram positifs à acide lipotéichoïque
CA2753287A1 (fr) 2009-02-24 2010-09-02 Glaxo Group Limited Constructions de liaison d'antigene
EP2401296A1 (fr) 2009-02-24 2012-01-04 Glaxo Group Limited Constructions multivalentes et/ou multispécifiques de liaison au rankl
WO2010097386A1 (fr) 2009-02-24 2010-09-02 Glaxo Group Limited Constructions de liaison d'antigène
CN102341412B (zh) 2009-03-05 2018-01-05 梅达雷克斯有限责任公司 特异于cadm1 的全人抗体
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
WO2010122090A1 (fr) 2009-04-24 2010-10-28 Glaxo Group Limited Combinaisons d'anticorps dirigés contre fgfr1c
EP2470569A1 (fr) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Anticorps anti-epha10
US20120269822A1 (en) 2009-10-20 2012-10-25 Marks James D Anti-Botulinum Neurotoxin a Single Domain Antibody Antibodies
WO2011054007A1 (fr) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 comme cible thérapeutique et diagnostique
US20120282276A1 (en) 2009-11-05 2012-11-08 The Regents Of The University Of Michigan Biomarkers predictive of progression of fibrosis
ES2724975T3 (es) * 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
US20120296403A1 (en) 2010-02-10 2012-11-22 Novartis Ag Methods and compounds for muscle growth
PT3904391T (pt) 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
CN106620692B (zh) 2010-04-09 2021-04-09 重症监护诊断股份有限公司 可溶性人st-2抗体和分析法
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (fr) 2010-05-06 2017-12-20 Novartis AG Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
EP2576621B1 (fr) 2010-05-27 2019-04-10 Genmab A/S Anticorps monoclonaux contre her2
CA2800769C (fr) 2010-05-27 2021-11-02 Genmab A/S Anticorps monoclonaux contre l'epitope de her2
SMT202000031T1 (it) 2010-06-09 2020-03-13 Genmab As Anticorpi contro cd38 umano
BR112012031727B1 (pt) 2010-06-15 2022-03-29 Genmab A/S Conjugado de droga-anticorpo, composição farmacêutica, e, uso do conjugado de droga- anticorpo
WO2012019168A2 (fr) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Acides nucléiques modifiés et leurs procédés d'utilisation
JP2013537416A (ja) 2010-08-13 2013-10-03 メディミューン リミテッド 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
ES2678145T3 (es) 2010-08-24 2018-08-09 Abbott Laboratories Anticuerpos específicos contra la proteína del núcleo del VIH y usos de los mismos
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
CN103328511B (zh) 2010-09-10 2016-01-20 埃派斯进有限公司 抗-IL-1β抗体及其使用方法
WO2012044992A2 (fr) 2010-09-30 2012-04-05 Agency For Science, Technology And Research (A*Star) Méthodes et réactifs de détection et de traitement de la métaplasie œsophagienne
EP2625189B1 (fr) 2010-10-01 2018-06-27 ModernaTX, Inc. Synthèse d'acides nucléiques et méthodes d'utilisation associées
AU2011333738A1 (en) 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
MX342810B (es) 2011-03-03 2016-10-13 Apexigen Inc Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
AU2012225246B2 (en) 2011-03-10 2016-01-21 Omeros Corporation Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
EP4520771A3 (fr) 2011-04-20 2025-07-16 Genmab A/S Anticorps bispecifiques contre her2
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CN103796678B (zh) 2011-04-20 2018-02-27 健玛保 针对her2的双特异性抗体
ES2709654T3 (es) 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
PL2726094T3 (pl) 2011-06-28 2017-06-30 Oxford Biotherapeutics Ltd Cel terapeutyczny i diagnostyczny
PL2726508T3 (pl) 2011-06-28 2017-12-29 Oxford Biotherapeutics Ltd Przeciwciała przeciwko cyklazie ADP-rybozylowej 2
AR086823A1 (es) 2011-06-30 2014-01-22 Genentech Inc Formulaciones de anticuerpo anti-c-met, metodos
CN103747807B (zh) 2011-07-05 2016-12-07 比奥阿赛斯技术有限公司 P97‑抗体缀合物和使用方法
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
AU2012294673B2 (en) 2011-08-05 2015-11-26 Bioasis Technologies Inc. p97 fragments with transfer activity
WO2013025446A2 (fr) 2011-08-12 2013-02-21 Omeros Corporation Anticorps monoclonaux anti-fzd10 et leurs procédés d'utilisation
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
CA2843771A1 (fr) 2011-09-20 2013-03-28 Eli Lilly And Company Anticorps anti-c-met
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
EP2785742B1 (fr) 2011-11-02 2020-01-08 Apexigen, Inc. Anticorps anti-kdr et procédés d'utilisation
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
SG11201402485UA (en) 2011-11-21 2014-06-27 Genentech Inc Purification of anti-c-met antibodies
EP2785741A1 (fr) 2011-12-02 2014-10-08 Cancer Research Technology Limited Anticorps dirigés contre le récepteur de hgf et leurs utilisations
EP3590538A1 (fr) 2011-12-05 2020-01-08 Novartis AG Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3)
CN104105709A (zh) 2011-12-05 2014-10-15 诺华股份有限公司 抗her3的结构域ii的表皮生长因子受体3(her3)抗体
CA3018046A1 (fr) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Nucleoside, nucleotide, et compositions d'acide nucleique modifies
ES2693593T3 (es) 2012-03-15 2018-12-12 Omeros Corporation Composición y método para la diversificación de secuencias diana
WO2013151665A2 (fr) 2012-04-02 2013-10-10 modeRNA Therapeutics Polynucléotides modifiés destinés à la production de protéines associées à une maladie humaine
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9248181B2 (en) 2012-04-20 2016-02-02 Merus B.V. Methods and means for the production of Ig-like molecules
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
EP3632462A1 (fr) 2012-07-06 2020-04-08 Genmab B.V. Protéine dimérique ayant des mutations triples
CA3140358A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014037419A1 (fr) * 2012-09-04 2014-03-13 Vib Vzw Domaines variables simples d'immunoglobuline dirigés contre le cd74 et leurs utilisations dérivées
US9714291B2 (en) 2012-10-05 2017-07-25 Kyowa Hakko Kirin Co., Ltd Heterodimer protein composition
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
WO2014087299A1 (fr) 2012-12-07 2014-06-12 Pfizer Inc. Fragments d'anticorps monomérique génétiquement modifié
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
US9856319B2 (en) 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
KR20200024345A (ko) 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
CA2902068C (fr) 2013-02-28 2023-10-03 Caprion Proteomics Inc. Biomarqueurs de la tuberculose et leurs utilisations
AU2014243816B2 (en) 2013-03-13 2019-01-31 Bioasis Technologies Inc. Fragments of p97 and uses thereof
EP3611189A1 (fr) 2013-03-14 2020-02-19 Novartis AG Anticorps dirigés contre notch 3
NZ629682A (en) 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG10201708048XA (en) 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
US20160108122A1 (en) * 2013-05-23 2016-04-21 Idac Theranostics, Inc. Therapeutic or prophylactic agent for immunodeficiency virus infection
ME03675B (fr) 2013-07-05 2020-10-20 Genmab As Anticorps anti-cd3 humanisés ou chimères
CA2919076C (fr) * 2013-07-31 2024-01-30 Amgen Inc. Stabilisation de polypeptides contenant une fc
CA2919790C (fr) 2013-08-02 2018-06-19 Pfizer Inc. Anticorps anti-cxcr4 et conjugues anticorps-medicaments
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015048744A2 (fr) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucléotides codant des polypeptides de modulation immunitaire
EP3052521A1 (fr) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucléotides codant pour un récepteur de lipoprotéines de faible densité
KR102243980B1 (ko) 2013-10-11 2021-04-26 리제너론 파마슈티칼스 인코포레이티드 대사적으로 최적화된 세포 배양
SI3071237T1 (sl) 2013-11-21 2024-11-29 Genmab A/S Liofilizirana formulacija konjugata protitelo-zdravilo
JP6603227B2 (ja) 2014-02-03 2019-11-06 バイオアシス テクノロジーズ インコーポレイテッド Ｐ９７融合タンパク質
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
CA3124228C (fr) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Animaux non humains qui produisent des proteines de liaison monodomaine
AU2015252906C1 (en) 2014-05-01 2020-09-17 Bioasis Technologies Inc. p97-polynucleotide conjugates
JP6827319B2 (ja) 2014-05-08 2021-02-10 中外製薬株式会社 Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
SMT202000265T1 (it) 2014-07-11 2020-07-08 Genmab As Anticorpi che legano axl
MA40609B1 (fr) 2014-09-05 2020-05-29 Janssen Pharmaceutica Nv Agents de liaison cd123 et leurs utilisations
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3233907B1 (fr) 2014-12-19 2021-03-03 Genmab A/S Protéines hétérodimères bispécifiques de rongeurs
WO2016102588A1 (fr) 2014-12-22 2016-06-30 Genmab A/S Procédé de production d'anticorps
US10544220B2 (en) 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
EP3291836A4 (fr) 2015-05-06 2018-11-14 Janssen Biotech, Inc. Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
PL3319993T3 (pl) 2015-07-10 2020-07-27 Genmab A/S Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017023863A1 (fr) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides et anticorps pour l'élimination de biofilms
WO2017027691A1 (fr) 2015-08-13 2017-02-16 New York University Molécules à base d'anticorps sélectives pour l'épitope {p} ser404 de tau et leurs utilisations dans le diagnostic et le traitement d'une tauopathie
WO2017027685A2 (fr) 2015-08-13 2017-02-16 New York University Molécules à base d'anticorps spécifiques de l'épitope asp421 tronqué de la protéine tau et leurs utilisations dans le diagnostic et le traitement de tauopathie
MX2018002043A (es) 2015-08-17 2018-07-06 Janssen Pharmaceutica Nv ANTICUERPOS ANTI-BCMA, MOLí‰CULAS DE UNIí“N A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
PT3347054T (pt) 2015-09-11 2021-07-15 Genmab As Regimes de dosagem para conjugados fármaco-anticorpo anti-tf
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3365027B1 (fr) 2015-10-14 2022-03-30 Research Institute at Nationwide Children's Hospital Anticorps spécifiques interférant avec hu et leur utilisation comme inhibiteur de biofilm
EA201891084A1 (ru) 2015-11-02 2019-10-31 Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
SI3383920T1 (sl) 2015-11-30 2024-06-28 The Regents Of The University Of California Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
KR20180101479A (ko) 2016-01-13 2018-09-12 젠맵 에이/에스 항체 및 그의 약물 접합체를 위한 제제
TW201734049A (zh) 2016-01-22 2017-10-01 健生生物科技公司 抗－ｒｏｒ１抗體、ｒｏｒ１ ｘ ｃｄ３雙特異性抗體及使用其之方法
KR20260018979A (ko) 2016-02-05 2026-02-09 젠맵 에이/에스 개선된 내재화 특징을 갖는 다중특이적 항원-결합 분자
BR112018068103A2 (pt) 2016-03-08 2019-01-15 Janssen Biotech Inc anticorpos gitr, métodos e usos
US20190233522A1 (en) 2016-07-08 2019-08-01 Genmab A/S New dosage regimens for antibody drug conjugates based on anti-axl antibodies
PH12018502613B1 (en) 2016-07-12 2023-02-01 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2018011421A1 (fr) 2016-07-14 2018-01-18 Genmab A/S Anticorps multispécifiques dirigés contre cd40 et cd137
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
ES3041722T3 (en) 2016-07-29 2025-11-14 Inst Nat Sante Rech Med Antibodies targeting tumor associated macrophages and uses thereof
TWI765900B (zh) 2016-08-03 2022-06-01 中國大陸商軒竹（北京）醫藥科技有限公司 哌唑黴素(plazomicin)抗體及使用方法
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
JP7075135B2 (ja) 2016-08-16 2022-05-25 ユニヴァーシティ オヴ メリーランド、バルティモア 増殖因子を標的とする二機能性分子を使用したがんの治療方法
US20190276549A1 (en) 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
WO2018089829A1 (fr) 2016-11-10 2018-05-17 Fortis Therapeutics, Inc. Cellules effectrices spécifiques de cd46 et leurs utilisations
BR112018014281A2 (pt) 2016-11-15 2018-12-18 H Lundbeck As agentes, usos e métodos para o tratamento da sinucleinopatia
CN110087763A (zh) 2016-11-22 2019-08-02 伊勒卓菲公司 包含治疗剂或诊断剂的颗粒和悬浮液以及其使用方法
JP2020503857A (ja) 2016-12-12 2020-02-06 セファイド 自動反応カートリッジにおける統合化イムノｐｃｒ及び核酸分析
EP3555127B1 (fr) 2016-12-16 2024-12-18 H. Lundbeck A/S Agents, utilisations et procédés
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CN110267985B (zh) 2017-01-04 2023-05-23 H.隆德贝克有限公司 用于治疗眼科疾病的特异性针对过度磷酸化τ蛋白的抗体
US11564982B2 (en) 2017-01-04 2023-01-31 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
EP3580233A1 (fr) 2017-02-10 2019-12-18 Genmab B.V. Variants polypeptidiques et ses utilisations
TW201834688A (zh) 2017-02-24 2018-10-01 日商中外製藥股份有限公司 藥學組成物、抗原結合分子、治療方法以及篩選方法
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
DK3592769T3 (da) 2017-03-09 2024-08-12 Genmab As Antistoffer mod pd-l1
WO2018170178A1 (fr) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition et procédés de rupture de biofilms bactériens sans inflammation associée
JP7330942B2 (ja) 2017-03-31 2023-08-22 ジェンマブ ホールディング ビー．ブイ． 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
CA3060514A1 (fr) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions et procedes pour le traitement d'inflammation pulmonaire
EP3655026A4 (fr) 2017-07-17 2021-07-28 Janssen Biotech, Inc. Régions de liaison à un antigène dirigées contre les domaines de la fibronectine de type iii et leurs procédés d'utilisation
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
WO2019036855A1 (fr) 2017-08-21 2019-02-28 Adagene Inc. Molécules anti-cd137 et leur utilisation
US11773171B2 (en) 2017-12-19 2023-10-03 Surrozen Operating, Inc. WNT surrogate molecules and uses thereof
CN117946267A (zh) 2017-12-19 2024-04-30 瑟罗泽恩奥普瑞汀公司 抗卷曲蛋白抗体和使用方法
CN111699003B (zh) 2017-12-19 2024-05-03 瑟罗泽恩奥普瑞汀公司 抗lrp5/6抗体和使用方法
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
MA51666A (fr) 2018-01-24 2020-12-02 Genmab Bv Variants polypeptidiques et leurs utilisations
WO2019148444A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps anti-ctla4 et leurs procédés de fabrication et d'utilisation
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
CN111787948A (zh) 2018-02-09 2020-10-16 健玛保 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
EP3765517A1 (fr) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles se liant à calréticuline et utilisations associees
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
AU2019247511B2 (en) 2018-04-06 2025-10-16 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CA3095986A1 (fr) 2018-04-10 2019-10-17 Genmab A/S Anticorps specifiques d'axl pour le traitement du cancer
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
TW202506732A (zh) 2018-05-07 2025-02-16 丹麥商珍美寶股份有限公司 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
UA130542C2 (uk) 2018-05-16 2026-03-18 Янссен Байотек, Інк. Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
WO2019226969A1 (fr) 2018-05-24 2019-11-28 Elektrofi, Inc. Particules comprenant un agent thérapeutique ou diagnostique et suspensions et leurs procédés d'utilisation
WO2019243636A1 (fr) 2018-06-22 2019-12-26 Genmab Holding B.V. Anticorps anti-cd37 et anticorps anti-cd20, compositions et méthodes d'utilisation de ceux-ci
CA3105448A1 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molecules d'anticorps anti-tcr et leurs utilisations
US20210292422A1 (en) 2018-07-05 2021-09-23 Surrozen, Inc. Multi-specific wnt surrogate molecules and uses thereof
US20200017600A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
EP3813867A1 (fr) 2018-07-22 2021-05-05 Bioasis Technologies Inc. Traitement de métastases lymphatiques
TW202021618A (zh) 2018-08-17 2020-06-16 美商２３與我有限公司 抗ｉｌ１ｒａｐ抗體及其使用方法
WO2020053122A1 (fr) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinaison d'anticorps her2/neu avec de l'hème pour le traitement du cancer
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
WO2020065396A1 (fr) 2018-09-26 2020-04-02 Genmab A/S Anticorps spécifiques d'axl pour le traitement du cancer du poumon non à petites cellules
EP3860715A1 (fr) 2018-10-04 2021-08-11 Genmab Holding B.V. Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
CN112771074A (zh) 2018-10-05 2021-05-07 国家儿童医院研究所 用于酶促破坏细菌生物膜的组合物和方法
MX2021004684A (es) 2018-10-23 2021-06-04 Glycardial Diagnostics S L Anticuerpos especificos para apoj glucosilada y usos de los mismos.
WO2020084056A1 (fr) 2018-10-25 2020-04-30 Swiss Pharma International Ag Anticorps anti-cd89 humains et leurs utilisations
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
JP7410143B2 (ja) 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
CA3118789A1 (fr) 2018-11-06 2020-05-14 Genmab A/S Formulation d'anticorps
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
AR117327A1 (es) 2018-12-20 2021-07-28 23Andme Inc Anticuerpos anti-cd96 y métodos de uso de estos
CA3120474A1 (fr) 2018-12-21 2020-06-25 23Andme, Inc. Anticorps anti-il-36 et leurs procedes d'utilisation
SG11202106603UA (en) 2018-12-21 2021-07-29 Sapreme Tech Bv Biologically active cluster of molecules
EP3917500A2 (fr) 2019-01-31 2021-12-08 Elektrofi, Inc. Formation et morphologie de particules
NL2022494B1 (en) 2019-02-01 2020-08-19 Lava Therapeutics B V Novel CD40-binding antibodies
CN113993893A (zh) 2019-02-01 2022-01-28 拉法医疗有限公司 新cd40结合抗体
CN119039441A (zh) 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
GB201903767D0 (en) * 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
EP3733707A1 (fr) 2019-04-30 2020-11-04 Celyad S.A. Cellules car-t de ciblage de bcma et leurs utilisations
US20220315661A1 (en) 2019-05-09 2022-10-06 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
AU2020311897A1 (en) 2019-07-08 2022-02-03 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms
MX2022000496A (es) 2019-07-12 2022-04-20 Janssen Pharmaceutica Nv Agentes de unión y usos de estos.
EP3999542A1 (fr) 2019-07-19 2022-05-25 Genmab A/S Conjugués médicament-anticorps anti-axl destinés à être utilisés dans le traitement du cancer
EP4003425A2 (fr) 2019-07-25 2022-06-01 Sapreme Technologies B.V. Saponine bioactive liée à une fraction fonctionnelle
JP7656587B2 (ja) 2019-08-15 2025-04-03 ジェンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体を含む薬学的組成物、ならびにそれらの使用
WO2021048423A1 (fr) 2019-09-12 2021-03-18 Genmab A/S Anticorps bispécifiques se liant à 5t4 et cd3 pour une utilisation dans le traitement du cancer
EP4027978A1 (fr) 2019-09-13 2022-07-20 Elektrofi, Inc. Compositions et procédés pour l'administration de produits biologiques thérapeutiques pour le traitement d'une maladie
EP3792283A1 (fr) 2019-09-16 2021-03-17 Lava Therapeutics B.V. Traitement du cancer comprenant l'administration d'anticorps de liaison du récepteur des lymphocytes t vgamma9vdelta2
WO2021058729A1 (fr) 2019-09-27 2021-04-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps dirigés contre le récepteur de type i d'une substance inhibitrice anti-mullérienne et leurs utilisations
EP4034560A1 (fr) 2019-09-27 2022-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps de de substance inhibitrice müllérienne et leurs utilisations
JP2023500701A (ja) 2019-11-06 2023-01-10 ジェンマブ ビー．ブイ． 抗体変種の組み合わせおよびその使用
EP4072682A1 (fr) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Anticorps présentant une spécificité pour her4 et leurs utilisations
KR20220128363A (ko) 2019-12-24 2022-09-20 제이제이피 바이오로직스 에스피. 제트 오.오. 항-인간 hvem(tnfrsf14) 항체 및 그의 용도
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
US20230272105A1 (en) 2020-01-16 2023-08-31 Genmab A/S Formulations of cd38 antibodies and uses thereof
WO2021155916A1 (fr) 2020-02-04 2021-08-12 BioNTech SE Traitement impliquant une vaccination d'antigène et des agents de liaison se liant à pd-l1 et cd137
EP4100059A1 (fr) 2020-02-04 2022-12-14 Genmab A/S Anticorps destinés à être utilisés en thérapie
MX2022009936A (es) 2020-03-18 2022-09-12 Genmab As Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
WO2021212019A1 (fr) 2020-04-17 2021-10-21 Elektrofi, Inc. Procédés de formation de particules par formation et déshydratation en continu de gouttelettes
KR20230004739A (ko) 2020-04-21 2023-01-06 제이제이피 바이오로직스 에스피. 제트 오.오. 인간화 항-인간 cd89 항체 및 이의 용도
US20230265204A1 (en) 2020-04-24 2023-08-24 Hoffmann-La Roche Inc. Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
MX2022013797A (es) 2020-05-08 2022-11-30 Genmab As Anticuerpos biespecificos contra cd3 y cd20.
JP2023524875A (ja) 2020-05-11 2023-06-13 ヤンセン バイオテツク，インコーポレーテツド 多発性骨髄腫を治療するための方法
CA3180683A1 (fr) 2020-05-12 2021-11-18 Inserm (Institut National De La Sante Et De La Recherche Medicale) Nouveau procede de traitement de lymphomes cutanes a lymphocytes t et de lymphomes derives de tfh
EP4559477A3 (fr) 2020-05-13 2025-08-13 Adagene AG Compositions et méthodes de traitement du cancer
WO2021243204A1 (fr) 2020-05-29 2021-12-02 23Andme, Inc. Anticorps anti-cd200r1 et méthodes d'utilisation associées
WO2021259880A1 (fr) 2020-06-22 2021-12-30 Almirall, S.A. Anticorps anti-il-36 et leurs procédés d'utilisation
KR20230042035A (ko) 2020-07-08 2023-03-27 라바 테라퓨틱스 엔.브이. Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체
EP3939999A1 (fr) 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Anticorps neutralisant la sous-unité alpha du récepteur de l'interleukine 11 (il11ra) et leurs utilisations
JP2023534726A (ja) 2020-07-23 2023-08-10 ジェンマブ ビー．ブイ． 多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用
KR20230065256A (ko) 2020-08-06 2023-05-11 비온테크 에스이 코로나바이러스 s 단백질용 결합제
EP4192511A1 (fr) 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Immunoconjugués ciblant cd46 et procédés d'utilisation associés
IL300835A (en) 2020-09-02 2023-04-01 Genmab As Antibody therapy
CN116782933A (zh) 2020-09-10 2023-09-19 健玛保 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
US20240034812A1 (en) 2020-09-10 2024-02-01 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
CA3189883A1 (fr) 2020-09-10 2022-03-17 Brian Elliott Anticorps bispecifique contre cd3 et cd20 en polytherapie de traitement d'un lymphome folliculaire
CA3190376A1 (fr) 2020-09-10 2022-03-17 Brian Elliott Anticorps bispecifique contre cd3 et cd20 en polytherapie pour le traitement d'un lymphome folliculaire
EP4210745A1 (fr) 2020-09-10 2023-07-19 Genmab A/S Anticorps bispécifique anti-cd3 et anti-cd20 en polythérapie pour traiter un lymphome diffus à grandes cellules b
KR20230066040A (ko) 2020-09-10 2023-05-12 젠맵 에이/에스 만성 림프구성 백혈병을 치료하기 위한 cd3 및 cd20에 대한 이중특이적 항체
IL301269A (en) 2020-09-14 2023-05-01 Ichnos Sciences S A Antibodies that bind to IL1RAP and their uses
TW202227478A (zh) 2020-09-15 2022-07-16 德商拜恩迪克公司 對細胞靶向遞送的藥劑及方法
JP2023547329A (ja) 2020-10-02 2023-11-10 ジェンマブ エー／エス Ｒｏｒ２へと結合することができる抗体ならびにｒｏｒ２およびｃｄ３に結合する二重特異性抗体
TW202237081A (zh) 2020-12-07 2022-10-01 德商生物新技術公司 抗體及紫杉烷合併療法
CA3200826A1 (fr) 2020-12-10 2022-06-16 Paul Willem Henri Ida PARREN Anticorps qui se lient aux recepteurs des lymphocytes t gamma-delta
US20250277031A1 (en) 2021-01-08 2025-09-04 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to cd47 and antigen-binding fragment thereof
WO2022148413A1 (fr) 2021-01-08 2022-07-14 北京韩美药品有限公司 Anticorps se liant de manière spécifique à 4-1bb et fragment de liaison à l'antigène de l'anticorps
EP4276466A4 (fr) 2021-01-08 2024-12-18 Beijing Hanmi Pharmaceutical Co., Ltd. Anticorps se liant spécifiquement avec pd-l1 et fragment de liaison à l'antigène d'anticorps
EP4281566A1 (fr) 2021-01-20 2023-11-29 Coding Bio Limited Procédés de criblage à haut rendement de récepteurs chimériques à l'antigène
GB202100754D0 (en) 2021-01-20 2021-03-03 Coding Bio Ltd Methods for high throughput screening of chimeric antigen receptors
JP2024507180A (ja) 2021-02-16 2024-02-16 ヤンセン ファーマシューティカ エヌ．ベー． Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
BR112023016360A2 (pt) 2021-02-16 2024-01-23 Janssen Biotech Inc Materiais e métodos para determinação aprimorada de ligante alvo
BR112023017099A2 (pt) 2021-02-26 2023-11-21 Lava Therapeutics N V Anticorpos que se ligam a cd123 e a receptores de células t gama-delta
IL305681A (en) 2021-03-09 2023-11-01 Genmab As Multispecific binding agents against cd40 and cd137 in therapy
MX2023010567A (es) 2021-03-12 2023-09-21 Genmab As Variantes de anticuerpos no activadoras.
JP7714675B2 (ja) 2021-03-24 2025-07-29 ヤンセン バイオテツク，インコーポレーテツド ＣＤ７９ｂ、ＣＤ２０、及びＣＤ３を標的とする三重特異性抗体
WO2022216993A2 (fr) 2021-04-08 2022-10-13 Marengo Therapeutics, Inc. Molécules multifonctionnelles se liant au tcr et leurs utilisations
WO2022234146A1 (fr) 2021-05-07 2022-11-10 Genmab A/S Compositions pharmaceutiques comprenant des anticorps bispécifiques se liant à b7h4 et cd3
US20240255517A1 (en) 2021-06-04 2024-08-01 Elektrofi, Inc. Methods For Screening Particle Formulations Comprising Proteins
US20250339533A1 (en) 2021-06-08 2025-11-06 Biontech Cell & Gene Therapies Gmbh Agents and methods for activation and targeting of immune effector cells
BR112023027006A2 (pt) 2021-06-21 2024-03-12 BioNTech SE Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
CA3225254A1 (fr) 2021-07-13 2023-01-19 BioNTech SE Agents de liaison multispecifiques contre cd40 et cd137 en polytherapie du cancer
IL309495A (en) 2021-07-15 2024-02-01 BioNTech SE Agents encoding cldn6 and cd3 binding elements for treating cldn6-positive cancers
WO2023023227A1 (fr) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Procédés de traitement de la drépanocytose ou de la bêta thalassémie en utilisant des inhibiteurs du trajet alternatif du complément
WO2023023220A1 (fr) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Méthodes de traitement de la drépanocytose ou de la bêta-thalassémie à l'aide d'un inhibiteur de la voie alterne du complément
MX2024002611A (es) 2021-08-30 2024-05-29 Lassen Therapeutics 1 Inc Anticuerpos anti-il-11ra.
IL311141A (en) 2021-09-06 2024-04-01 Genmab As Antibodies capable of binding to CD27, their variants and uses thereof
CN119053340A (zh) 2021-10-06 2024-11-29 健玛保 针对pd-l1和cd137的多特异性结合剂与抗pd-1抗体组合用于治疗癌症
EP4413040A1 (fr) 2021-10-06 2024-08-14 Genmab A/S Agents de liaison multispécifiques dirigés contre pd-l1 et cd137 en combinaison
EP4413039A1 (fr) 2021-10-08 2024-08-14 Genmab A/S Anticorps se liant à cd30 et cd3
JP2024538958A (ja) 2021-10-21 2024-10-28 ラヴァ・セラピューティクス・エヌ・ヴイ ガンマデルタｔ細胞活性化抗体の使用
MX2024005392A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
WO2023083439A1 (fr) 2021-11-09 2023-05-19 BioNTech SE Agoniste de tlr7 et combinaisons pour le traitement du cancer
GB202116514D0 (en) 2021-11-16 2021-12-29 Coding Bio Ltd Computational methods for the design and optimisation of chimeric antigen receptors (cars)
MX2024008833A (es) 2022-01-28 2024-07-25 Genmab As Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia combinada para tratar linfoma difuso de celulas b grandes.
CN118647402A (zh) 2022-01-28 2024-09-13 健玛保 用于治疗弥漫性大b细胞淋巴瘤的联合疗法中的针对cd3和cd20的双特异性抗体
AU2023214781A1 (en) 2022-02-02 2024-08-15 BioNTech SE Cyclic epitope tags
CA3250175A1 (fr) 2022-02-02 2023-08-10 BioNTech SE Agents et méthodes pour une administration ciblée en direction de cellules
JP2025507295A (ja) 2022-02-02 2025-03-18 バイオエヌテック エスエー 細胞への核酸の標的化送達のための薬剤および方法
EP4238988A1 (fr) 2022-03-01 2023-09-06 Consejo Superior De Investigaciones Científicas Anticorps dirigés contre le sars-cov-2 et leurs utilisations
WO2023174521A1 (fr) 2022-03-15 2023-09-21 Genmab A/S Agents de liaison se liant à epcam et cd137
WO2023175171A1 (fr) 2022-03-18 2023-09-21 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anticorps de polyomavirus bk et leurs utilisations
WO2023186905A1 (fr) 2022-03-29 2023-10-05 LAVA Therapeutics N.V. Procédé de traitement d'un cancer hématologique après le criblage de cellules tumorales cd1d-positives
US20250304689A1 (en) 2022-04-13 2025-10-02 Genmab A/S Bispecific antibodies against cd3 and cd20
CN119403542A (zh) 2022-04-29 2025-02-07 伊勒卓菲公司 可注射悬浮液
EP4522657A1 (fr) 2022-05-12 2025-03-19 Genmab A/S Agents de liaison capables de se lier à cd27 en polythérapie
WO2023218051A1 (fr) 2022-05-12 2023-11-16 Genmab A/S Agents de liaison capables de se lier à cd27 en polythérapie
EP4285926A1 (fr) 2022-05-30 2023-12-06 LAVA Therapeutics N.V. Traitement combiné de la leucémie lymphocytaire chronique
EP4292609A1 (fr) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Compositions comprenant des anticorps se liant aux récepteurs de lymphocytes t gamma-delta
EP4292610A1 (fr) 2022-06-15 2023-12-20 LAVA Therapeutics N.V. Anticorps variants se liant aux récepteurs de lymphocytes t gamma-delta
NL2032398B1 (en) 2022-07-06 2024-01-23 Academisch Ziekenhuis Leiden Bispecific antibody and uses thereof
AU2023317702A1 (en) 2022-08-01 2025-01-09 BioNTech SE Nucleic acid compositions comprising amphiphilic oligo ethylene glycol (oeg)-conjugated compounds and methods of using such compounds and compositions
CN117586388A (zh) 2022-08-09 2024-02-23 深圳智源生物医药有限公司 改进的β淀粉样蛋白寡聚体特异性结合抗体
CN120018862A (zh) 2022-08-31 2025-05-16 阿雷克森制药公司 用于治疗镰状细胞病的融合多肽的剂量和施用
WO2024052503A1 (fr) 2022-09-08 2024-03-14 Institut National de la Santé et de la Recherche Médicale Anticorps présentant une spécificité pour ltbp2 et leurs utilisations
EP4587473A1 (fr) 2022-09-12 2025-07-23 Institut National de la Santé et de la Recherche Médicale Nouveaux anticorps anti-itgb8 et leurs utilisations
GB202214132D0 (en) 2022-09-27 2022-11-09 Coding Bio Ltd CLL1 binding molecules
EP4628505A1 (fr) 2022-10-28 2025-10-08 Genor Biopharma Co., Ltd. Nouvel anticorps anti-ctla4
TW202432177A (zh) 2022-10-31 2024-08-16 丹麥商珍美寶股份有限公司 Ｃｄ３８抗體及其用途
EP4612179A1 (fr) 2022-11-02 2025-09-10 Genmab A/S Anticorps bispécifiques dirigés contre cd3 et cd20 pour le traitement du syndrome de richter
CN120302979A (zh) 2022-12-01 2025-07-11 生物技术公司 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗
CN120787238A (zh) 2023-01-06 2025-10-14 拉森医疗公司 用于治疗甲状腺眼病的抗IL-11Rα抗体
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
WO2024165146A1 (fr) 2023-02-07 2024-08-15 Biontech Cell & Gene Therapies Gmbh Cellules effectrices immunitaires exprimant de manière stable et transitoire des acides nucléiques
GB202301949D0 (en) 2023-02-10 2023-03-29 Coding Bio Ltd CLL1 and/or CD33 binding molecules
EP4438624A1 (fr) 2023-03-27 2024-10-02 LAVA Therapeutics N.V. Anticorps se liant aux récepteurs des lymphocytes t nectin-4 et gamma-delta
AR132290A1 (es) 2023-04-05 2025-06-11 Genmab As Composiciones farmacéuticas que comprenden anticuerpos que se unen a cd30 y cd3
CN121620391A (zh) 2023-04-06 2026-03-06 金麦安博股份有限公司 用于治疗癌症的针对pd-l1和cd137的多特异性结合剂
CN121311504A (zh) 2023-04-13 2026-01-09 金麦安博股份有限公司 用针对cd3和cd20的双特异性抗体治疗淋巴瘤的方法
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
TW202509077A (zh) 2023-06-30 2025-03-01 丹麥商珍美寶股份有限公司 與纖維母細胞活化蛋白α及死亡受體４結合之抗體
WO2025012417A1 (fr) 2023-07-13 2025-01-16 Institut National de la Santé et de la Recherche Médicale Anticorps à fragments longs anti-neurotensine et anti-neuromédine n et leurs utilisations
WO2025021277A1 (fr) 2023-07-21 2025-01-30 BioNTech SE Agents et procédés d'administration ciblée de cytokines à des cellules immunitaires
WO2025024780A1 (fr) 2023-07-27 2025-01-30 LAVA Therapeutics N.V. Anticorps se liant aux récepteurs des lymphocytes t gamma-delta pour traiter le cancer
WO2025026553A1 (fr) 2023-08-02 2025-02-06 BioNTech SE Agents et méthodes pour une administration ciblée en direction de cellules
TW202523699A (zh) 2023-08-02 2025-06-16 德商拜恩迪克公司 靶向傳遞免疫效應子細胞之藥劑及方法
WO2025032158A1 (fr) 2023-08-08 2025-02-13 Institut National de la Santé et de la Recherche Médicale Méthode de traitement de tauopathies
AU2024324215A1 (en) 2023-08-11 2026-02-26 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025054552A1 (fr) 2023-09-08 2025-03-13 Elektrofi, Inc. Particules et suspensions comprenant des agents de dégradation d'hyaluronane et leurs procédés d'utilisation
WO2025056180A1 (fr) 2023-09-15 2025-03-20 BioNTech SE Procédés de traitement faisant appel à des agents se liant à epcam et cd137 en combinaison avec des antagonistes de liaison à l'axe pd-1
WO2025073890A1 (fr) 2023-10-06 2025-04-10 Institut National de la Santé et de la Recherche Médicale Procédé de capture de vésicules extracellulaires tumorales circulantes
AU2024360228A1 (en) 2023-10-11 2026-03-19 BioNTech SE Agents and methods for targeted delivery of immune effector cells
GB202317065D0 (en) 2023-11-07 2023-12-20 Coding Bio Ltd BCMA binding molecules
WO2025111402A1 (fr) 2023-11-21 2025-05-30 Board Of Regents Of The University Of Nebraska Anticorps anti-amyloïde bêta et compositions associées et méthodes associées
WO2025114411A1 (fr) 2023-11-29 2025-06-05 Institut National de la Santé et de la Recherche Médicale Nouvelle méthode de traitement de troubles cérébraux ou neurologiques
TW202540189A (zh) 2023-11-30 2025-10-16 德商生物新技術公司 在組合療法中能夠結合ｏｘ４０之抗體
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025134050A1 (fr) 2023-12-21 2025-06-26 Janssen Biotech, Inc Anticorps trispécifique ciblant bcma, gprc5d et cd3 pour le traitement du myélome multiple
WO2025134049A1 (fr) 2023-12-21 2025-06-26 Janssen Biotech, Inc Anticorps trispécifique ciblant bcma, gprc5d et cd3 pour le traitement de l'amylose al
WO2025224297A1 (fr) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Anticorps ayant une spécificité vis-à-vis de tgfbi et leurs utilisations
WO2025233825A1 (fr) 2024-05-06 2025-11-13 Janssen Pharmaceutica Nv Enrichissement de cellules exprimant un lieur bird
WO2025240670A2 (fr) 2024-05-15 2025-11-20 Abalytics Oncology, Inc. Anticorps anti-pd-1 et molécules de liaison associées et procédés et utilisations associés
WO2025242732A1 (fr) 2024-05-21 2025-11-27 Institut National de la Santé et de la Recherche Médicale Anticorps pan dirigés contre la protéine de spicule du sars-cov-2 et leurs utilisations à des fins thérapeutiques
WO2025242827A1 (fr) 2024-05-22 2025-11-27 Genmab A/S Anticorps bispécifique contre pd-l1 et cd137 en polythérapie
WO2025242910A1 (fr) 2024-05-23 2025-11-27 Egle Therapeutics Anticorps agonistes d'il18r et leurs utilisations
EP4653460A1 (fr) 2024-05-23 2025-11-26 Egle Therapeutics Anticorps agonistes de l'il18r et leurs utilisations
WO2025243243A1 (fr) 2024-05-24 2025-11-27 Janssen Biotech, Inc. Anticorps bispécifique ciblant emr2 (cd312) et récepteur de lymphocytes t trbv19
WO2025248097A2 (fr) 2024-05-31 2025-12-04 Gamamabs Pharma Anticorps anti-her3 humain humanisés et leurs utilisations
WO2025257181A1 (fr) 2024-06-11 2025-12-18 Institut National de la Santé et de la Recherche Médicale Anticorps ciblant la protéine-43 de liaison à l'adn à réponse trans-active (tdp-43)
WO2026011013A1 (fr) 2024-07-02 2026-01-08 Epibiologics, Inc. Agents de liaison et leurs utilisations
WO2026017820A1 (fr) 2024-07-18 2026-01-22 Egle Therapeutics Protéine de fusion pour le traitement du cancer
EP4681780A1 (fr) 2024-07-18 2026-01-21 Egle Therapeutics Immunocytokine pour le traitement du cancer
WO2026027759A1 (fr) 2024-08-02 2026-02-05 BioNTech SE Agents et méthodes pour une administration ciblée à des cellules
WO2026037841A1 (fr) 2024-08-12 2026-02-19 ONA Therapeutics S.L. Molécules anti-fgfr4 et leurs utilisations
WO2026050572A2 (fr) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Molécules multifonctionnelles se liant au tcr et leurs utilisations
WO2026062193A1 (fr) 2024-09-20 2026-03-26 BioNTech SE Compositions et procédés
WO2026078647A1 (fr) 2024-10-11 2026-04-16 Janssen Biotech, Inc. Combinaison d'un anticorps trispécifique ciblant bcma, gprc5d et cd3 et de pomalidomide pour le traitement du myélome multiple
WO2026078659A1 (fr) 2024-10-11 2026-04-16 Janssen Biotech, Inc. Combinaison d'un anticorps trispécifique ciblant bcma, gprc5d et cd3 et d'un anticorps anti-cd38 pour le traitement du myélome multiple

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
WO1997033617A1 (fr) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Proteines hybrides de ligand fas et leurs utilisations
EP0953639A1 (fr) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH Anticorps dirigé contre FAPalpha pouvant être produit avec une efficacité accrue
DE69934694T2 (de) 1998-08-10 2007-10-04 Agensys, Inc., Santa Monica Bpc-1: ein ausgeschiedenes gehirnspezifisches protein das von prostata- und blasen-krebszellen exprimiert und ausgeschieden wird
US7083784B2 (en) * 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7754208B2 (en) * 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
WO2002070009A1 (fr) * 2001-02-27 2002-09-12 Yasuda, Yoshiko Medicaments preventifs/curatifs pour cicatrices hypertrophiques, cheloides et maladies arthritiques chroniques
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002305478A1 (en) 2001-06-20 2003-01-08 Molecular Staging, Inc. Conjugates of reduced antibodies and biomolecules
US7053202B2 (en) * 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040092719A1 (en) 2002-09-17 2004-05-13 Eszter Birck-Wilson Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
WO2004042017A2 (fr) * 2002-10-31 2004-05-21 Genentech, Inc. Methodes et compositions pouvant augmenter la production d'anticorps
US7438907B2 (en) 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
PT1606318E (pt) * 2003-03-26 2009-11-10 Deutsches Krebsforsch Proteínas de fusão de fc melhoradas
CA2526274C (fr) 2003-05-30 2015-12-01 Agensys, Inc. Variants de l'antigene de cellules souches de la prostate (psca) et utilisations subsequentes de ceux-ci
US20050069521A1 (en) 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
WO2005063815A2 (fr) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Variants de polypeptides de liaison au recepteur fc$g(g) et procede apparentes
ES2383300T3 (es) * 2003-11-13 2012-06-20 Hanmi Holdings Co., Ltd Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
PT1718677E (pt) 2003-12-19 2012-07-18 Genentech Inc Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos
US20080318212A1 (en) * 2004-04-06 2008-12-25 Wilson Cindy A Orphan Receptor Tyrosine Kinase as a Target in Breast Cancer
AU2005334481A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
US20060074225A1 (en) 2004-09-14 2006-04-06 Xencor, Inc. Monomeric immunoglobulin Fc domains
EP1810979B1 (fr) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. ANTICORPS IgG4 HUMAINS STABILISES
EP2354163A3 (fr) 2005-09-26 2013-04-24 Medarex, Inc. Conjugué d'un anticorps anti-CD4 ou anti-PSMA et duocarmycine
TW200732350A (en) * 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
CA2631184A1 (fr) 2005-11-28 2007-05-31 Genmab A/S Anticorps monovalents recombines et leurs procedes de production
US9181344B2 (en) 2005-12-15 2015-11-10 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
JP5511654B2 (ja) * 2007-05-31 2014-06-04 ゲンマブ エー／エス 分子操作により得られた組換え非グリコシル化一価半抗体
EP2152751A1 (fr) 2007-05-31 2010-02-17 Genmab A/S Protéines de fusion ou liéee à demi-vie étendue

Also Published As

Publication number Publication date
JP5525729B2 (ja) 2014-06-18
KR20150041197A (ko) 2015-04-15
US10155816B2 (en) 2018-12-18
US20090226421A1 (en) 2009-09-10
CA2631184A1 (fr) 2007-05-31
KR101866623B1 (ko) 2018-07-04
EA016609B1 (ru) 2012-06-29
EA200801460A1 (ru) 2009-02-27
US20190169298A1 (en) 2019-06-06
AU2006317242A1 (en) 2007-05-31
BRPI0619056A2 (pt) 2011-09-20
JP2016182138A (ja) 2016-10-20
JP2014128266A (ja) 2014-07-10
WO2007059782A1 (fr) 2007-05-31
JP2009517006A (ja) 2009-04-30
US20220396629A1 (en) 2022-12-15
KR20080090406A (ko) 2008-10-08
JP6341954B2 (ja) 2018-06-13
EP1973576A1 (fr) 2008-10-01
EP1973576B1 (fr) 2019-05-15
JP6039542B2 (ja) 2016-12-07

Similar Documents

Publication Publication Date Title
SG10201600950TA (en) Recombinant monovalent antibodies and methods for production thereof
EP2121756A4 (fr) Anticorps et procedes de fabrication et d'utilisation de ceux-ci
IL240245A (en) 5t4 antibodies and their uses
IL191820A0 (en) Anti-ox40l antibodies and methods using same
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
IL222922A (en) Antibodies against neurophilin-1 and their use
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
GB2467830B (en) Mutant proteins and methods for producing them
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
ZA201001260B (en) Immunogenic polypeptides and monoclonal antibodies
IL231891A0 (en) Anti-2ephriinb antibodies and methods of using them
EP1921122A4 (fr) Matériau amortissant et son procédé de production
GB0517487D0 (en) Antibodies
IL212731A0 (en) Anti-ferroportin 1 monoclonal antibodies and uses thereof
ZA200804337B (en) Recombinant monovalent antibodies and methods for production thereof
EP1799252A4 (fr) Méthode de production d'anticorps
EP1896047A4 (fr) Anticorps anti-gfralpha3
GB0505489D0 (en) Antibodies
HK1120438A (en) Recombinant monovalent antibodies and methods for production thereof
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
GB0505054D0 (en) Antibodies
GB0512278D0 (en) Antibodies
IL177448A0 (en) Methods for protein production
GB0519883D0 (en) Antibodies
PL1951759T3 (pl) Przeciwciała anty-EGFR